Customize
Quick Links
Past Events

Accreditation/
Credit Designation

Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC designates this live activity is for a maximum of 8.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians' Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669 for 8.25 Contact Hours.

Acknowledgment of Commercial Support

This activity is supported by educational grants from AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Bristol-Myers Squibb, Celgene Corporation, Lilly, Merck Sharp & Dohme Corp., Pfizer, and Takeda Oncology.

About
Accreditation
Privacy Policy
Terms & Conditions
Executive Board
Journal
Faculty Portal
Contact
Facebook
Twitter
LinkedIn
Google +
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 1-609-378-3701

Copyright © 2018
Physicians’ Education Resource ®, LLC.
All rights reserved.

13th Annual New York Lung Cancers Symposium

13th Annual New York Lung Cancers Symposium


13th Annual New York Lung Cancers Symposium

Saturday, November 10, 2018
New York Marriott Marquis
1535 Broadway

New York, NY 10036
(888) 523-0366

Overview:

At the 13th Annual New York Lung Cancers Symposium, you will experience a comprehensive overview of lung cancer diagnosis and multidisciplinary treatment. For 2018, we have redesigned the meeting to help you increase your knowledge and competence of lung cancer therapy, starting with the roles that surgery, radiology, pulmonology, and pathology play in ensuring the most accurate diagnosis of lung cancers. You will also hear experts from the New York area discuss optimal approaches for early-stage and locally advanced disease, as well as hear them present the latest data on immunotherapy and targeted agents in metastatic lung cancers. Finally, you will get a preview of upcoming advances in local and systemic therapies for thoracic malignancies.
 
As in previous years, interactive case challenges will provide you with an opportunity to discuss the application of clinical data to real-world patient cases. For nurse practitioners and physician assistants, a special breakfast session will provide opportunities for learning and networking. We look forward to offering you this exciting meeting, centered around lung cancers, that will foster collaboration between yourselves and other members of the multidisciplinary oncology team. This is a program you won’t want to miss!

What you will learn at the New York Lung Cancers Symposium: 

  • Multidisciplinary approaches for patient diagnosis
  • Perioperative strategies for your patients with resectable disease
  • Immunotherapy and local modalities for stage III lung cancers
  • Targeting immune checkpoints and oncogenic drivers in your patients with metastatic lung cancers
  • Application of clinical data in challenging case scenarios

Benefits of Attending

  • Network with your peers
  • Ask questions about your most challenging cases to the faculty
  • Apply testing strategies to optimize tumor characterization and inform clinical decision-making for the management of patients with lung cancers
  • Evaluate recent and emerging evidence concerning single agent and combination immunotherapeutic approaches to manage lung cancers

Acknowledgment of Commercial Support

This activity is supported by educational grants from AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Bristol-Myers Squibb, Celgene Corporation, Lilly, Merck Sharp & Dohme Corp., Pfizer, and Takeda Oncology.

For further information concerning Lilly grant funding visit www.lillygrantoffice.com.

Target Audience

This educational activity is directed toward medical oncologists, radiation oncologists, thoracic surgeons, pulmonologists involved in the treatment and management of patients with lung cancer. Fellows, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of lung cancer may also participate.

Learning Objectives

Upon completion of this activity, participants should be better prepared to:

  • Apply testing strategies to optimize tumor characterization and inform clinical decision-making for the management of patients with lung cancers
  • Integrate prognostic and biomarker findings to inform personalized treatment planning and sequencing for patients with NSCLC and SCLC
  • Evaluate recent and emerging evidence concerning single agent and combination immunotherapeutic approaches to manage lung cancers
  • Explain current and emerging oncogene-driven NSCLC subtypes in the context of optimizing therapeutic sequencing for multiple lines of therapy
  • Determine optimized strategies for patients without mutations including the role of chemotherapies and antiangiogenic strategies in these settings
  • Assess proactive strategies to plan for and mitigate the impact of treatment-related toxicities in the care of patients with lung cancers

Program Chairs

Mark G. Kris, MD
Attending, Thoracic Oncology Service
William and Joy Ruane Chair in Thoracic Oncology
Memorial Sloan Kettering Cancer Center
New York, NY
 

Roman Perez-Soler, MD
Chairman, Department of Oncology
Montefiore Medical Center
Professor of Medicine and Molecular Pharmacology
Deputy Cancer Center Director
Albert Einstein College of Medicine
Bronx, NY







Become a Member

Forgot Password?
Filter By